Pharmaceutical Business review

Wyeth to expand nutritional manufacturing facility in Singapore

The state-of-the-art facility, utilizing the strictest operational and quality standards, will produce key brands of Wyeth nutritional products for infants and toddlers, including formula and milk products sold as Progress and Promise. The expansion is said to increase the plant’s capacity by 50%, enabling the facility to increase its supply to the Singapore market, as well as manufacturing additional product for export to other key markets throughout the Asia Pacific region.

Expansion at the Tuas site is the final phase of a $500 million capital improvement project in the Asia Pacific region, which includes previously announced investments to Wyeth’s global nutritional manufacturing and supply operations in China and the Philippines.

Mark Larsen, president, Asia Pacific and Nutritionals, Wyeth Pharmaceuticals, said: A key element of our company’s mission is ensuring that infants and children have access to the best and highest-quality products. This site will help us to continue to achieve that objective.